Antigen Presentation Articles & Analysis

The Native Antigen Company Limited (‘NAC’: Oxford, UK) announces the launch of a new range of Dengue Virus-Like Particles incorporating products for all four Dengue serotypes. Virus-Like Particles (VLPs) represent an increasingly important technology for use in vaccine development and serology. VLPs consist of protein shells comprising outer proteins specific to the virus in ...

By The Native Antigen Company

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed ...

By Evaxion Biotech A/S

Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer microenvironment and immune ...

By Creative Biolabs

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting (aAPC) cell program, RTX-321, at the American ...

By Rubius Therapeutics, Inc.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted ...

By Beyond Air Inc

ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...

By Immunadd, Inc.

Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th. ANGANY’s primary focus is the development of therapeutic vaccines, leveraging the unique immunogenicity and safety profile of its ...

By Angany Inc.

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...

By Obsidian Therapeutics, Inc.

Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...

By Alfa Chemistry

T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), ...

By T-Knife GmbH

CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient ...

By CD Genomics

BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the ...

By BlueWillow Biologics

Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists. ...

By PsiOxus Therapeutics Ltd.

Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dosing Patients in Phase 1 Clinical Trial of RTX-224 in Select ...

By Rubius Therapeutics, Inc.

Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...

By Immune-Onc Therapeutics, Inc.

VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Corporation ...

By NEC OncoImmunity AS 

Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats. Infectious diseases are disorders caused by organisms — such as bacteria, ...

By Protheragen

NanoPin Technologies, Inc., whose mission is to develop advanced diagnostics to improve the lives of millions of individuals affected by infectious disease, announces the formation of a collaboration with Thermo Fisher Scientific to refine the liquid chromatography mass spectrometry (LCMS)-based workflow to allow robust and highly sensitive clinical application of NanoPin’s proprietary ...

By NanoPin Technologies Inc.

Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. The data confirm the potential of V-306 for ...

By Virometix AG

Abera Bioscience AB (“Company” or “Abera”) initiated research and development in immuno-oncology in 2021 with a first sub-goal to explore the potential of the company’s platform in the area and to carry out initial studies for further prioritization. In accordance with the press release regarding a private placement sent out December 23rd, in which Abera informed ...

By Abera Bioscience AB